Abstract
Salicylate is the basic therapy for Kawasaki disease, however its optimal dose is controversial. We investigated the therapeutic efficacy of high dose (100 mg/kg per day,n=30) versus low dose (30 mg/kg per day,n=30) salicylate. Duration of fever, SGPT, serum salicylate, plasma thromboxane B2 (TxB2) and 6-ketoprostaglandin F1α (PGF1α) levels were compared before enrollment and on days 4,7 and 14 of treatment. In the high dose group, duration of fever was significantly shorter than that of the low dose group (3.2±0.3 versus 5.4±0.8 days,P<0.05), however, SGPT levels were significantly elevated (157±34 versus 48±11 IU/l,P<0.05). No differences in the incidence of coronary artery lesions were observed (5/30 versus 7/30). Plasma TxB2 production was completely blocked in both groups, and plasma 6-keto-PGF1α levels in the high dose group on day 14 was lower than that in the low dose group (39±8 versus 159±65 pg/ml,P<0.05). SGPT and plasma 6-keto-PGF1α correlated with serum salicylate concentration. These data suggest that high dose salicylate therapy may be disadvantageous as anti-thrombotic therapy, and supports the notion that low dose therapy is safe in the acute stage of Kawasaki disease.
Similar content being viewed by others
Abbreviations
- 6-keto-PGF1α:
-
6-keto-prostaglandin F1α
- TxB2 :
-
thromboxane B2
References
Amano S, Hayama F, Tasaka K, Kubagawa H, Hamashima Y (1979) Pathology of Kawasaki disease. Pathology and morphogenesis of the vascular changes. Jpn Circ J 43:633–634
Awakura M, Asai T (1986) The hepatic damage on Kawasaki disease and therapy. Prog Med (In Japanese) 6:162–168
Burch JW, Stanford N, Majerus PW (1978) Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61:314–319
Burns JC, Glode MP, Clarke SH, Wiggins J, Hathaway WE (1984) Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients a high risk for development of coronary artery aneurysms. J Pediatr 105:206–211
Fujiwara T, Fujiwara H, Ueda T, Nishioka K, Hamashima Y (1986) Comparison of macroscopic, ppstmortem, angiographic and two-dimensional echocardiographic findings of coronary aneurysms in children with Kawasaki disease. Am J Cardiol 57:761–764
Fulton DR, Meissner HC, Peterson MB (1988) Effects of current therapy of Kawasaki disease on eicosanoid metabolism. Am J Cardiol 61:1323–1327
Hamasaki Y, Ichimura T, Hattori T, Tasaki H, Miyazaki S (1986) Aspirin therapy for Kawasaki disease (MCLS): action for arachidonic acid metabolism in platelets and vascular endothelium. Acta Paediatr Jpn (In Japanese) 90:2214–2222
Hamasaki Y, Ichimura T, Tasaki H, Miyazaki S (1988) Studies on the effect of long-term use of low dose aspirin in Kawasaki disease. Acta Paediatr Jpn Overseas ed 30:63–67
Hanley SP, Bevan J, Cockbill SR, Heptinstall S (1981) Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet I: 969–971
Hicks RV, Melish ME (1986) Kawasaki syndrome. Pediatr Clin North Am 33:1151–1175
Hidaka T, Nakano M, Ueta T, Komatsu Y, Yamamoto M (1983) Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease. J Pediatr 102:94–96
Jacobs JC (1979) Salicylate treatment of epidemic Kawasaki disease in New York City. Ther Drug Monit 1:123–130
Kato H, Koike S, Yokoyama T (1979) Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 63:175–179
Kato H, Inoue O, Akagi T (1988) Kawasaki disease: cardiac problems and management. Pediatr Rev 9:209–217
Koren G, MacLeod SM (1984) Difficulty in achieving therapeutic serum concentrations of salicylates in Kawasaki disease. J Pediatr 105:991–995
Koren G, Rose V, Lavi S, Rowe R (1985) Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease. JAMA 254:767–769
Koren G, Schaffer F, Silverman E, Walker S, Duffy C, Stein L, Suria D, Schue S, Thiessen JJ, Gelfand E, Laxer R (1988) Determination of low serum concentrations of salicylates in patients with Kawasaki disease. J Pediatr 112:663–667
Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341–347
Research Committee on Kawasaki disease (1984) Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Ministry of Health and Welfare, Tokyo, Japan
Sasaguri Y, Kato H (1982) Regression of aneurysms in Kawasaki disease: a pathological study. J Pediatr 100:225–231
Sasai K (1988) Plasma PGE2, TxB2, 6-keto PGF1α levels in patients with Kawasaki disease. Allergy (In Japanese) 37:952–958
Sasai K, Furukawa S, Yabuta K (1987) The metabolism of the archidonic cascade in patients with Kawasaki disease. In: Shulman ST (ed) Kawasaki disease. Alan R. Liss, New York, pp 565–566
Takahashi M, Kato H (1987) Can consensus be reached in cardiac management of Kawasaki syndrome?: review of a survey among Japanese and U.S. pediatric cardiologists. In: Shulman ST (ed) Kawasaki disease. Alan R. Liss, New York, pp 493–508
The Kawasaki disease research committee (1986) A randomized controlled study of three different therapies for patients having Kawasaki disease. Act Paediatr Jpn (in Japanese) 90: 1844–1849
Yokoyama T, Kato H, Ichinose E (1980) Aspirin treatment and platelet function in Kawasaki disease. Kurume Med J 27:57–61
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Akagi, T., Kato, H., Inoue, O. et al. Salicylate treatment in Kawasaki disease: high dose or low dose?. Eur J Pediatr 150, 642–646 (1991). https://doi.org/10.1007/BF02072625
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02072625